Celldex Therapeutics opened lower at $29.72, compared with its previous close of $30.15. In the last trading session, the stock traded between $28.46 and $30.01. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Celldex Therapeutics is now worth
$ 64.20
Resulting in a loss of
$ 35.80 (35.80%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 11 Analysts
Buy
90.91%
Hold
9.09%
Sell
0%
Markets Today
Today's Change
$-1.64 (-5.45%)
Day High
$30.01
Day Low
$28.46
Day Open
$29.72
Prev Close
$30.15
Volume
5,98,489
1W Return
-4.69%
1M Return
-3.18%
3M Return
-35.64%
6M Return
-11.69%
1Y Return
16.98%
Fundamentals
Market Cap ($ Mn)
2,239
PE Ratio
-
PB Ratio
4.30
PEG Ratio
-
ROE
-40.04%
ROCE
-39.76%
EPS (TTM)
$-0.96
Investment Returns
1 Week
-4.69%
1 Month
-3.18%
3 Months
-35.64%
6 Months
-11.69%
9 Months
15.88%
Financials
Quarterly
All values in $ Mn
0.7
Mar 25
0.7
Jun 25
0.0
Sep 25
0.1
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
9Nov
Canaccord Genuity raises Celldex Therapeutics price target to $68
Canaccord Genuity raised the price target to $68. Previous price target was set at $60. Analyst Edward Nash maintains a Buy rating.
3 days ago
9Nov
Morgan Stanley raises Celldex price target to $61, maintains Overweight
Morgan Stanley raised Celldex Therapeutics' price target to $61. Previous price target was set at $57. Analyst Judah Frommer maintains an Overweight rating. Price target increase amounts to $4 per share.
Celldex Therapeutics filed a mixed shelf offering with the SEC. The total size of the offering is currently undisclosed. Mixed shelf allows issuance of various security types over time.
7 days ago
22Sep
Celldex barzolvolimab meets Phase 3 endpoints in CSU trials
Celldex barzolvolimab met all primary and secondary endpoints in Phase 3 CSU trials. Trials randomized 1,939 patients, representing the largest program for antihistamine-refractory CSU. Drug showed efficacy in patients refractory to Novartis' Xolair (omalizumab). Shares fell 12.51% to $36.65 despite positive clinical results.
1mo ago
7Aug
Celldex Q2 EPS beats estimates despite sales miss
Celldex Therapeutics beat Q2 EPS estimates with $(0.94) per share but missed sales estimates significantly. The company reported a net loss of $73.5 million, driven by R&D costs for barzolvolimab trials. Cash reserves increased to $717.6 million, funding operations through 2028.
3mo ago
23Jul
Wells Fargo lowers Celldex target to $48
Brokerage firms have adjusted price targets for Celldex Therapeutics, with Wells Fargo, Morgan Stanley, and Cantor Fitzgerald lowering their objectives while Guggenheim raised its target. All firms maintained positive ratings.
